- Home
- TENB vs KRYS Comparison
TENB vs KRYS Comparison
Compare TENB & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | KRYS |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 9.6B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TENB | KRYS |
|---|---|---|
| Price | $30.11 | $347.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 11 |
| Target Price | $31.69 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 3.6M | 200.3K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 128.00 |
| EPS | 0.05 | ★ 3.62 |
| Revenue | ★ $999,405,000.00 | $389,130,000.00 |
| Revenue This Year | $9.37 | $38.74 |
| Revenue Next Year | $7.04 | $32.53 |
| P/E Ratio | $673.40 | ★ $96.16 |
| Revenue Growth | 11.04 | ★ 33.94 |
| 52 Week Low | $15.73 | $145.46 |
| 52 Week High | $43.67 | $382.54 |
Technical Indicators
Market Signals| Indicator | TENB | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 48.23 |
| Support Level | $31.97 | $289.36 |
| Resistance Level | $39.45 | $382.33 |
| Average True Range (ATR) | 1.91 | 11.24 |
| MACD | -0.38 | -0.73 |
| Stochastic Oscillator | 4.01 | 28.36 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.